Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the depression in Alzheimer's disease study

Research output: Contribution to journalArticle

Abstract

Objective: This study evaluated the efficacy and safety of sertraline in the treatment of major depression in 22 outpatients with Alzheimer's disease. Method: Twelve of the 22 patients were given sertraline and 10 were given placebo by random group assignment for 12 weeks. Response to treatment was measured by using the Cornell Scale for Depression in Dementia. The patients were also assessed with the Hamilton Depression Rating Scale, the activities of daily living subscale of the Psychogeriatric Dependency Rating Scales, and the Mini-Mental State. Results: After 12 weeks of double-blind, placebo-controlled treatment, nine of the patients given sertraline and two of those given placebo were at least partial responders. Patients given sertraline had significantly greater mean declines from baseline in Cornell Scale for Depression in Dementia scores; the bulk of antidepressant response occurred by the third week of treatment. Conclusions: Sertraline is superior to placebo in reducing depression in patients with Alzheimer's disease who also suffer from major depression.

Original languageEnglish (US)
Pages (from-to)1686-1689
Number of pages4
JournalAmerican Journal of Psychiatry
Volume157
Issue number10
DOIs
StatePublished - 2000

Fingerprint

Sertraline
Alzheimer Disease
Placebos
Clinical Trials
Depression
Dementia
Therapeutics
Geriatric Psychiatry
Activities of Daily Living
Antidepressive Agents
Outpatients
Safety

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

@article{40bfabf223f440b7957c3069ae625512,
title = "Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the depression in Alzheimer's disease study",
abstract = "Objective: This study evaluated the efficacy and safety of sertraline in the treatment of major depression in 22 outpatients with Alzheimer's disease. Method: Twelve of the 22 patients were given sertraline and 10 were given placebo by random group assignment for 12 weeks. Response to treatment was measured by using the Cornell Scale for Depression in Dementia. The patients were also assessed with the Hamilton Depression Rating Scale, the activities of daily living subscale of the Psychogeriatric Dependency Rating Scales, and the Mini-Mental State. Results: After 12 weeks of double-blind, placebo-controlled treatment, nine of the patients given sertraline and two of those given placebo were at least partial responders. Patients given sertraline had significantly greater mean declines from baseline in Cornell Scale for Depression in Dementia scores; the bulk of antidepressant response occurred by the third week of treatment. Conclusions: Sertraline is superior to placebo in reducing depression in patients with Alzheimer's disease who also suffer from major depression.",
author = "Lyketsos, {Constantine G} and Leoutsakos, {Jeannie-Marie S} and Steele, {C. D.} and S. Kopunek and Steinberg, {Martin I} and Baker, {A. S.} and Jason Brandt and Rabins, {Peter V}",
year = "2000",
doi = "10.1176/appi.ajp.157.10.1686",
language = "English (US)",
volume = "157",
pages = "1686--1689",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "10",

}

TY - JOUR

T1 - Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease

T2 - Initial results from the depression in Alzheimer's disease study

AU - Lyketsos, Constantine G

AU - Leoutsakos, Jeannie-Marie S

AU - Steele, C. D.

AU - Kopunek, S.

AU - Steinberg, Martin I

AU - Baker, A. S.

AU - Brandt, Jason

AU - Rabins, Peter V

PY - 2000

Y1 - 2000

N2 - Objective: This study evaluated the efficacy and safety of sertraline in the treatment of major depression in 22 outpatients with Alzheimer's disease. Method: Twelve of the 22 patients were given sertraline and 10 were given placebo by random group assignment for 12 weeks. Response to treatment was measured by using the Cornell Scale for Depression in Dementia. The patients were also assessed with the Hamilton Depression Rating Scale, the activities of daily living subscale of the Psychogeriatric Dependency Rating Scales, and the Mini-Mental State. Results: After 12 weeks of double-blind, placebo-controlled treatment, nine of the patients given sertraline and two of those given placebo were at least partial responders. Patients given sertraline had significantly greater mean declines from baseline in Cornell Scale for Depression in Dementia scores; the bulk of antidepressant response occurred by the third week of treatment. Conclusions: Sertraline is superior to placebo in reducing depression in patients with Alzheimer's disease who also suffer from major depression.

AB - Objective: This study evaluated the efficacy and safety of sertraline in the treatment of major depression in 22 outpatients with Alzheimer's disease. Method: Twelve of the 22 patients were given sertraline and 10 were given placebo by random group assignment for 12 weeks. Response to treatment was measured by using the Cornell Scale for Depression in Dementia. The patients were also assessed with the Hamilton Depression Rating Scale, the activities of daily living subscale of the Psychogeriatric Dependency Rating Scales, and the Mini-Mental State. Results: After 12 weeks of double-blind, placebo-controlled treatment, nine of the patients given sertraline and two of those given placebo were at least partial responders. Patients given sertraline had significantly greater mean declines from baseline in Cornell Scale for Depression in Dementia scores; the bulk of antidepressant response occurred by the third week of treatment. Conclusions: Sertraline is superior to placebo in reducing depression in patients with Alzheimer's disease who also suffer from major depression.

UR - http://www.scopus.com/inward/record.url?scp=0033797633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033797633&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.157.10.1686

DO - 10.1176/appi.ajp.157.10.1686

M3 - Article

C2 - 11007727

AN - SCOPUS:0033797633

VL - 157

SP - 1686

EP - 1689

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 10

ER -